Poster Session B

Thursday, January 17
12:30-3:00 p.m.

B01 Genome-scale shRNA screen provides insight into the role of CUL3 in adaptive mechanisms of resistance to mutant BRAF inhibition. Eliot Zhu. University of Iowa, Iowa City, IA.

B02, PR18 Comparative screening of skin-derived NCSCs, melanocytes, and melanoma developmental programs reveals LPAR1 in MAPKi resistance. Vito Rebecca. Wistar Institute, Philadelphia, .

B03, PR05 Unique lipid metabolite profiling in BRAFV600E inhibitor drug-resistant melanoma and their potential as drug target. Meng-Ting Chang. Agricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan.

B04, PR17 Sleeping Beauty mutagenesis reveals a Src-dependent DBL GEF family signaling mechanism driving MAPK inhibitor resistance in BRAF mutant melanoma. Christopher Stipp. University of Iowa, Iowa City, Iowa.

B05 Sox10 differentially regulates receptor tyrosine kinase expression in melanomas. Claudia Capparelli. Thomas Jefferson University, Philadelphia, PA.

B06 Loss of SPRY1 expression in BRAF-mutant cutaneous melanoma inhibits cell proliferation and improves response to targeted therapy. Elisabetta Fratta. Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Aviano (PN), Italy.


B08 Identification and characterization of Rho family GTPases as drivers of drug resistance in BRAFV600E mutant melanoma. Jacob Schillo. University of Iowa, Iowa City, IA.

B09 Nitric Oxide Stimulates PI3K-AKT Pathway Activation by S-Nitrosylation of PTEN in Human Melanoma Cells. Zhen Ding. Department of Melanoma Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX.


B13 Intrinsic microsomal PGE2 synthase-1 associates with poor patient survival and T cell infiltration, and regulates immunosuppression in human and mouse melanoma models. Sun-Hee Kim. The University of Texas MD Anderson Cancer Center, Houston, TX.

B14, PR15 CD74 regulated inflammatory pattern is associated with TIL growth and favorable response to adoptive immunotherapy. Suhendan Ekmekcioglu. UT., MD Anderson Cancer Center, Houston, TX.


B16 The immune profile of sentinel lymph nodes in melanoma. Georgia Beasley. Duke University, Durham, NC.

B17 VEGF removal delays the onset of acquired resistance to target therapy and increase the efficacy of immune checkpoint inhibitors in BRAF mutated melanoma. Valentina Comunanza. Department of Oncology – University of Turin; Candiolo Cancer Institute FPO-IRCCS, Candiolo, Torino, Italy.

B18 The expression of CD74-regulated inflammatory markers in Stage IV melanoma: Risk of CNS metastasis and patient survival. Dai Ogata. UT MD Anderson Cancer Center, Houston, Texas.

B19 Suppression of CD8+ T cell functions by melanoma cell-derived exosomes captured from plasma of patients with melanoma. Priyanka Sharma. University of Pittsburgh, Pittsburgh, PA.

B20 Monitoring of melanoma progression utilizing multi-platform biomarkers of blood cell-free DNA. Dave Hoon. John Wayne Cancer Institute, Santa Monica, CA.

B21 Arylsulfatase B (ARSB) is reduced in melanoma metastases and decline in ARSB increases programmed death-ligand (PDL)1. Joanne Tobacman. University of Illinois at Chicago and Jesse Brown VAMC, Chicago, IL.

B22, PR11 Understanding the role of myddosome dynamics in melanoma using live cell imaging. Bridget Kreger. AstraZeneca, Waltham, MA.

B24, PR12 Regulation of the tumor suppressive miR-29 family by oncogenic MAPK signaling in melanoma. Olga Vera. Moffitt Cancer Center, Tampa, FL.

B25 Demographic characteristics and peripheral blood clinical laboratory variables predict irAE occurrence in patients with advanced melanoma receiving anti-PD-1 monotherapy. Xue Bai. MGH, Boston, MA.

B26 Combinational effect of sulforaphane (SFN) and epigenetic demethylation agent 5-aza-2'-deoxycytidine (DAC) on metastatic melanoma. Tung-chin Chiang. University of Arkansas for Medical Sciences, Little Rock, AR.


B29  Systemic anti-melanoma immunity induced by oncolytic adenovirus Delta-24-RGDOX.  Hong Jiang. MD Anderson Cancer Center, Houston, Texas.

B30  The histone demethylase PHF8 epigenetically regulates the TGFbeta pathway to promote melanoma metastasis.  Rana Moubarak. NYU School of Medicine, New York, NY.

B31  Strategic investments by the Melanoma Research Alliance in research and career development accelerate progress in melanoma prevention, diagnostics and treatment.  Kristen Mueller. Melanoma Research Alliance, Washington, DC.

B32  A novel combination therapy for metastatic melanoma potentiates a gap junction positive feedback mechanism.  Shoshanna Zucker. D'Youville School of Pharmacy, Buffalo, NY.